{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-26-000031","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2026-06-05T16:03:46+00:00","discovered_at":"2026-06-05T16:05:00.247291+00:00","generated_at":"2026-06-05T16:05:11.600376+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"AbCellera appoints Dr. Victor Sandor as independent director to board","bullets":["Appointed Victor Sandor, M.D.C.M., to Board as independent director effective June 1, 2026.","Dr. Sandor brings oncology drug development expertise; previously CMO at Array BioPharma.","He secured approval of Braftovi and Mektovi at Array and contributed to Jakafi and Faslodex development.","Sandor currently serves on boards of ADC Therapeutics, Kymera Therapeutics, and Prelude Therapeutics.","Will not serve on any board committees initially; compensated per non-employee director policy."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-26-000031","json":"https://secwatch.observer/filing/0001703057-26-000031.json","markdown":"https://secwatch.observer/filing/0001703057-26-000031.md","text":"https://secwatch.observer/filing/0001703057-26-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000031/0001703057-26-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000031/abcl-20260601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T16:05:11.600376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1991527ed5","claim":"Victor Sandor was appointed as Director at AbCellera Biologics Inc..","evidence_excerpt":"On June 1, 2026, the Board of Directors (the \"Board\") of AbCellera Biologics Inc. (the \"Company\") appointed Victor Sandor as a new director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000031/0001703057-26-000031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}